Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 1/2023

01.02.2023 | editorial

Radiooncology and nuclear medicine

verfasst von: Alexander Haug

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten


Both in radiolo-oncology with percutaneous radiotherapy and in nuclear medicine with radionuclide therapy, significant progress has been achieved in recent years. In particular, with the aid of optimized imaging, but also through technical improvements, progress has been made with the aim of increasing effectiveness and, in turn, reducing toxicity as much as possible. In this issue, two articles will exemplify these advances. In the first article, Professor Lipp uses the example of imaging and therapy of prostate carcinomas to highlight the increasing importance of the nuclear medicine principle of theranostics [1]. In this principle, a target structure (in this case prostate-specific membrane antigen, PSMA) is addressed with the same ligand but different radionuclides. For diagnostic purposes, a positron emitter is used for positron-emission tomography (PET), and for therapeutic purposes an alpha or beta emitter is used. This makes it possible to determine at the diagnostic stage whether the therapeutic target structure is present in all tumor manifestations, thus, enabling targeted therapy and identifying patients with a low probability of response even before therapy begins. 68Ga-PSMA PET/CT has become the gold standard in the diagnosis of biochemical recurrence and provides a high probability of localizing recurrence even at very low PSA levels starting at 0.2 ng/ml, thus, enabling appropriate therapy. Therapy with 177Lu-PSMA has been shown to be effective and relatively well tolerated in a large phase III trial and has also currently received approval from the European Medicines Agency for castration-refractory metastatic prostate cancer. The article also illuminates that therapy with 177Lu-PSMA is more effective and less toxic than chemotherapy with cabazitaxel. Overall, a significant increase in this therapy is expected in the future. …
Radiooncology and nuclear medicine
verfasst von
Alexander Haug
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076

Weitere Artikel der Ausgabe 1/2023

memo - Magazine of European Medical Oncology 1/2023 Zur Ausgabe